Accès gratuit
| Numéro |
Med Sci (Paris)
Volume 21, Numéro 6-7, Juin–Juillet 2005
|
|
|---|---|---|
| Page(s) | 669 - 670 | |
| Section | Derniére Heure | |
| DOI | https://doi.org/10.1051/medsci/2005216-7669 | |
| Publié en ligne | 15 juin 2005 | |
- Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) : classification of myeloid neoplasms. Blood 2002; 100 : 2292–302. [Google Scholar]
- Wong S, Witte ON. The BCR-ABL story : bench to bedside and back. Annu Rev Immunol 2004; 22 : 247–306. [Google Scholar]
- Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002; 16 : 1207–12. [Google Scholar]
- Gotlib J, Cools J, Malone JM, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia implications for diagnosis, classification and management. Blood 2004; 103 : 2879–91. [Google Scholar]
- Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004; 104 : 1931–9. [Google Scholar]
- Wadleigh M, De Angelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia : tyrosine kinase inhibitors in others malignancies. Blood 2005; 105 : 22–30. [Google Scholar]
- Pahl HL. Towards a molecular understanding of polycythemia rubra vera. Eur J Biochem 2000; 267: 3395–401. [Google Scholar]
- Spivak JL. Polycythemia vera : myths, mechanisms, and management. Blood 2002; 100 : 4272–90. [Google Scholar]
- Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004; 32 : 179–87. [Google Scholar]
- James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434 : 1144–8. [Google Scholar]
- Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30 : 229–36. [Google Scholar]
- Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365 : 1054–61. [Google Scholar]
- Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352 : 1779–90. [Google Scholar]
- Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7 : 387–97. [Google Scholar]
- Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in Polycythemia vera. J Biol Chem 2005 online. [Google Scholar]
- Goldman JM. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 2005; 352 : 1744–6. [Google Scholar]
- Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders : it all makes sense. Blood 2005; 105 : 4187–90. [Google Scholar]
- Shannon K, Van Etten RA. JAKing up hematopoietic proliferation. Cancer Cell 2005; 7 : 291–3. [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.